Member Info for EmeraldCarrots

Corryvreckan1.

"The FTSE 250 changes take place in June.".

----------------------------------

No. The RNS says tomorrow:-

Index Effective FromStart of Trading

FTSE AIM UK 50 Index 02 May 2025

FTSE AIM 100 Index 02 May 2025

FTSE AIM All-Share Index 02 May 2025

https://www.lse.co.uk/rns/GAMA/gamma-communications-kn382sgy8paxr0i.html

Huge news coming, obviously. Gulp!

Bid?

Drug BB-1709 the Nr1. feature as well:-

https://www.blissbiopharma.com/Details?article_id=132

In circulating tumor cells:-

https://angleplc.com/wp-content/uploads/2025/04/AACR-Chicago-2025-_-Poster-1981.pdf

=========================

This information is invaluable. Using the analysis of circulating tumour cells (CTC's) what this shows is a cancer can be monitored to see if the treatment is working or not! This is why the big pharma Co's like Astrazeneca really need to step up and finance one or more cancer drug trials using Angle's Parsortix and Bioview system. Don't they want to find out more about the real-life effect of their drugs? Look at the poster. What can now be done if there in black and white. Analysing this data (especially using A.I) would glean invaluable information from a drug trial with say 200 participants. It's got to happen.

All IMHO.

In circulating tumor cells:-

https://angleplc.com/wp-content/uploads/2025/04/AACR-Chicago-2025-_-Poster-1981.pdf

On here. 100% lies are common. Make your own mind up. When Angle Plc get the next Pharma contract with Astra, Eisai, Bliss Pharma or whoever you know the sp will spike right?

Angle Plc now have the Illumina / Angle plc offering on their site:-

"Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer".

Molecular analysis of circulating tumour cells at the same time as CtDna analysis of the same tube of blood finds about twice as many biomarkers.........

https://angleplc.com/laboratory-services/

All IMHO.

That actually have cancer drugs that are cleared for use get their biomarker info from the original tissue sample. Unfortunately, his information will without doubt sometimes be out of date and wrong (because cancer changes over time) resulting in the patient receiving treatment that won't work! But what do they care? Not a lot seems to be the answer. The tech is there to re-evaluate the cancer to make sure it has not changed since the tissue biopsy. Trouble is not one of the multibillion-pound pharma Co's is willing to spend what....... £10 million to confirm. It's a total disgrace in my opinion. The ridiculous thing is if it can be confirmed in a cancer trial they will more than likely find more people to treat with their expensive drugs making even more money. The accountants don't see it like that as they are fools. I am of the opinion Astrazeneca will take the plunge.............. eventually. It is not a "plunge" actually as this sort of money is peanuts to them in reality.

All IMHO.

Treatment. Interesting. From Angle's web site:-

"Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer".

From A.I on google:-

"Enhertu is suitable for NSCLC when the tumor has activating HER2 (ERBB2) mutations, which are detected by an FDA-approved test. These mutations are in the HER2 gene, specifically leading to changes in the HER2 protein, that make it a suitable target for Enhertu".

Testing circulating tumour cells to find out if a cancer is suitable for AstraZeneca’s Enhertu drug using the Angle/Illumina partnership seems nailed on.

https://angleplc.com/laboratory-services/

All IMHO.

Custom 79-gene panel targeting lung cancer".

https://angleplc.com/laboratory-services/

Molecular analysis:

Next generation sequencing (NGS) dual analysis of CTC-DNA and cfDNA from a single blood tube. Two workflows, both using CTCs harvested using Parsortix technology:

Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer

ANGLE’s proprietary workflow using a 61 gene pan-cancer NGS panel with blocker displacement amplification

"Pleased to announce the presentation of new data for ANGLE's HER2-CTC assay at the American Association for Cancer Research (AACR) Annual meeting being held in Chicago.". Will Astrazeneca be interested?

https://www.lse.co.uk/rns/AGL/results-supporting-angle8217s-her2-assay-programme-goibxvtrt7yxndn.html

"Market access routes and reimbursement strategies defined in key initial international target countries, including the Middle East region, with well-positioned and aligned in-country distributors, with required regulatory certification (CE-IVD under IVDR) on track for April 2025"..

It would not take much for Genedrive to become very busy. Adoption by national health services or even fairly large private hospital Companies could easily mean hundreds of orders.

All IMHO.

"The British Summer Time (BST) is 6 hours ahead of Central Daylight Time (CDT).".

CDT time is 6hrs behind us. So the presentation in USA won't start until 3pm our time Monday.

Our market open for the first 1.5 hours of it. Interesting!

Big profits, dividend and the recent sp drop was due to 1 shareholder forced sell, and now they are all but out.

Up 2.95% and loads and loads nore to come.

All IMHO.

For the Genedrive® CYP2C19 is what will move the sp here. American players will suddenly be very interested. Clearance usually between 2 and 4 months from application. So a possibility of clearance about 8 weeks from application. Application is expected shortly after the CE clearance expected **next week**. The sp will be North of 3p after the FDA application.

All IMHO.

I was half expecting the sp to have already taken off. Maybe later today.

From American Association for Cancer Research.

2025 April 25-30; Chicago, IL.

https://www.aacr.org/meeting/aacr-annual-meeting-2025/

1. 1981 / 16 - Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells

April 28, 2025, 9:00 AM - 12:00 PM.

- Angle and Bioview results of study.

2. Poster presentation on ART0380:

Abstract Title: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors

Presenter: Helen M. R. Robinson, VP of Biology, Artios

Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1

Date Monday, April 28, 2025

Time: 2:00 pm – 5:00 pm CDT

Location: Section 16

The full poster abstract is available on the AACR Annual Meeting website.

- Artios update on ATR inhibitor, ART0380. DDR damage measured using Parsortix. Possibly follow on phase 3 trial!!!

===================================

https://www.artios.com/press-release/artios-pharma-announces-details-of-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025/

Should be interesting.

Https://www.linkedin.com/posts/genedrive-plc_gdr-activity-7321488162772459520-WZrN?utm_medium=ios_app&rcm=ACoAAD95sPkBUr5mkGDyDsztb6lzJVrZ20jCkj8&utm_source=social_share_send&utm_campaign=copy_link

What could they mean?

2pm announcement?

I was half expecting the sp to have already taken off. Maybe later today.

From American Association for Cancer Research.

2025 April 25-30; Chicago, IL.

https://www.aacr.org/meeting/aacr-annual-meeting-2025/

1. 1981 / 16 - Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells

April 28, 2025, 9:00 AM - 12:00 PM.

- Angle and Bioview results of study.

2. Poster presentation on ART0380:

Abstract Title: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors

Presenter: Helen M. R. Robinson, VP of Biology, Artios

Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1

Date Monday, April 28, 2025

Time: 2:00 pm – 5:00 pm CDT

Location: Section 16

The full poster abstract is available on the AACR Annual Meeting website.

- Artios update on ATR inhibitor, ART0380. DDR damage measured using Parsortix. Possibly follow on phase 3 trial!!!

===================================

https://www.artios.com/press-release/artios-pharma-announces-details-of-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025/

Should be interesting.

Smithfields

"AGL would have to have been granted permission to use Ilumina's reference....which could be a positive sign."

=============================

Good news yes. Hopefully Angle will get their bit on the Illumina web site in return in due course. Can't wait for that!